ADC Therapeutics SA (ADCT) vs Keros Therapeutics (KROS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Keros Therapeutics (KROS) has outperformed ADC Therapeutics SA (ADCT) over the past year, losing 25.9% versus a loss of 62.3%. Over five years, KROS leads with a -69.4% price change compared with -93.2% for ADCT. Keros Therapeutics is the larger company by market cap ($236.9 million vs $220.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADCT | KROS |
|---|---|---|
| Share price | $1.73 | $11.95 |
| Market cap | $220.87M | $236.93M |
| 1-day change | +8.81% | +2.66% |
| YTD return | -50.99% | -41.31% |
| 1-year return | -62.31% | -25.87% |
| 5-year return | -93.21% | -69.35% |
| EPS (TTM) | $-0.60 | $-3.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.98 | $22.55 |
| 52-week low | $0.78 | $9.69 |
| Distance from 52-week high | -65.26% | -47.01% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +92.49% | +65.94% |
| Average volume | 1.45M | 193.04K |
| Shares outstanding | 127.67M | 19.83M |
| Employees | 188 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KROS has outperformed ADCT by 36.4 percentage points over the past year.
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Health Care · Biotechnology: Pharmaceutical Preparations · 188 employees
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
ADCT vs KROS FAQ
Which is bigger, ADC Therapeutics SA or Keros Therapeutics?
Keros Therapeutics (KROS) is larger, with a market capitalization of $236.93M compared with $220.87M for ADC Therapeutics SA (ADCT).
Which stock has performed better over the past year, ADCT or KROS?
KROS returned -25.87% over the past 12 months, compared with -62.31% for ADCT (price return, excluding dividends). Past performance does not predict future results.
Are ADC Therapeutics SA and Keros Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.